Status:
TERMINATED
Tetanus Immunization in Subjects With No Immunization History or With Tetanus Antibody Levels Below Protective Levels
Lead Sponsor:
Grifols Therapeutics LLC
Conditions:
Tetanus
Eligibility:
All Genders
18-90 years
Phase:
PHASE4
Brief Summary
The goal of this study is to re-evaluate the tetanus antibody pharmacokinetic profile when Tetanus Immune Globulin (Human)(TIG) and Tetanus vaccine (Tetanus toxoid; TT) are given concurrently with str...
Detailed Description
This is a prospective, open-label, single-center trial including a single group of subjects with no known primary immunization history with TT or \>10 years have passed since the last dose of tetanus ...
Eligibility Criteria
Inclusion
- Age between 18 and 90 years.
- Signed a written informed consent prior to initiation of any study-related procedures.
- No known primary immunization history with TT/dT or \>10 years have passed since the last dose of tetanus containing vaccine was received. Subjects with unknown or uncertain previous vaccination histories are considered to have no previous tetanus and toxoid doses. Subjects who have had military service since 1941 will be considered to have had 1 dose of tetanus vaccine.
- Subjects must have documented tetanus antibody levels that are non-protective levels (\< 0.15 IU/ml).
- Subjects must be free of any presenting wound or wound infection
Exclusion
- History or suspicion of significant allergic reaction to intravenous immune globulin, and or blood products
- A history of selective IgA deficiency (serum level \<5.0 mg/dL) and known antibodies to IgA
- Congestive heart failure (New York Association stage greater than Class II)
- Conditions whose symptoms and effects could alter protein catabolism and/or IgG utilization (e.g. protein-losing enteropathies, nephrotic syndrome)
- Women of child bearing potential who do not practice adequate contraception (i.e. chemical or mechanical methods) and pregnant or lactating females
- Subjects who have severe thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections
- TIG therapy within the previous six months
- Investigational drug therapy within the previous three months
- History of Thromboembolism
Key Trial Info
Start Date :
March 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2007
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT00437671
Start Date
March 1 2007
End Date
September 1 2007
Last Update
January 20 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Long Island Jewish Medical Center
New Hyde Park, New York, United States, 11040